Drug
D0301 | Trifluoperazine
N
N05AB06 Trifluoperazine
[N05AB] Phenothiazines with piperazine structure
[N05A] ANTIPSYCHOTICS
[N05] PSYCHOLEPTICS
[N] Nervous system
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| UNCOUPLING | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | increase | 53 | |||
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | intravenous | 29mg/kg (29mg/kg) | Psychopharmacology Service Center, Bulletin. Vol. 2, Pg. 17, 1963. | |
| mouse | LD50 | oral | 1350mg/kg (1350mg/kg) | Psychopharmacology Service Center, Bulletin. Vol. 2, Pg. 17, 1963. | |
| mouse | LD50 | intraperitoneal | 120mg/kg (120mg/kg) | Neuropharmacology. Vol. 9, Pg. 235, 1970. | |
| 10-(.gamma.-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiozine | 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine | 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine |
| 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine | 10-(3-(4-methylpiperazin-1-yl)propyl)-2-(trifluoromethyl)-10H-phenothiazine | 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine |
| 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE | 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine | 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine # |
| 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)phenothiazine;hydrochloride | 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine | 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine |
| 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride | 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine;hydrochloride | 10-[3-(4-methylpiperazino)propyl]-2-(trifluoromethyl)phenothiazine;hydrochloride |
| 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- | 10H-Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)- | 117-89-5 |
| 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine | 2-Trifluoromethyl-10-[3'-(1-methyl-4-piperazinyl)propyl]phenothiazine | 214IZI85K3 |
| 5858-EP2302003A1 | 5858-EP2309505A1 | 605-75-4 |
| AB00053558 | AB00053558-27 | AB00053558_28 |
| AB00053558_29 | AKOS001487920 | AX8155275 |
| Apo-trifluoperazine (TN) | BDBM79181 | BIDD:PXR0132 |
| BPBio1_000338 | BPBio1_001345 | BRD-K89732114-001-02-6 |
| BRD-K89732114-001-03-4 | BRD-K89732114-001-05-9 | BRD-K89732114-300-05-5 |
| BRD-K89732114-300-07-1 | BSPBio_000306 | BSPBio_001190 |
| BSPBio_002928 | Bio1_000458 | Bio1_000947 |
| Bio1_001436 | Bio2_000435 | Bio2_000915 |
| Biomol-NT_000060 | C07168 | C21H24F3N3S |
| CAS-440-17-5 | CCG-37306 | CCRIS 6994 |
| CHEBI:45951 | CHEMBL422 | Calmazine |
| D08636 | DB00831 | DTXSID1046928 |
| DivK1c_000843 | EINECS 204-219-4 | FT-0650159 |
| Fluoperazine | Fluoperazine (Salt/Mix) | Flurazine |
| GTPL214 | HMS1362L11 | HMS1792L11 |
| HMS1990L11 | HMS2089J11 | HMS3429O07 |
| HSDB 3195 | IDI1_000843 | IDI1_002190 |
| Jatroneural (Salt/Mix) | KBio1_000843 | KBio2_000530 |
| KBio2_001148 | KBio2_002431 | KBio2_003098 |
| KBio2_003716 | KBio2_004999 | KBio2_005666 |
| KBio2_006284 | KBio2_007567 | KBio3_000959 |
| KBio3_000960 | KBio3_002148 | KBio3_002910 |
| KBioGR_000530 | KBioGR_000835 | KBioGR_002431 |
| KBioSS_000530 | KBioSS_001148 | KBioSS_002437 |
| KSC-210-031 | KUC109776N | L001075 |
| LS-105595 | Lopac-T-8516 | Lopac0_001232 |
| M989 | MCULE-3726407978 | MLS001146870 |
| MLS002702821 | MLS006011857 | MRF-0000088 |
| NCGC00013226 | NCGC00013226-02 | NCGC00013226-03 |
| NCGC00013226-04 | NCGC00013226-05 | NCGC00013226-06 |
| NCGC00013226-07 | NCGC00013226-08 | NCGC00013226-09 |
| NCGC00013226-10 | NCGC00013226-11 | NCGC00013226-12 |
| NCGC00013226-13 | NCGC00013226-15 | NCGC00024251-03 |
| NCGC00024251-04 | NCGC00024251-05 | NCGC00024251-06 |
| NCGC00024251-07 | NCI17474 | NCI60_001427 |
| NCI60_004087 | NCIStruc1_001127 | NCIStruc2_001093 |
| NINDS_000843 | NSC 17474 | NSC 46061 |
| NSC-17474 | NSC17474 | PDSP1_001300 |
| PDSP2_001284 | Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- | Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)- |
| Prestwick0_000313 | Prestwick1_000313 | Prestwick2_000313 |
| Prestwick3_000313 | Q1752915 | QTL1_000085 |
| RP 7623 | SBI-0051199.P003 | SC-95890 |
| SCHEMBL24866 | SKF 5019 | SMR001566649 |
| SPBio_000755 | SPBio_002525 | SR-01000003020-6 |
| STK182873 | Spectrum2_000828 | Spectrum3_001374 |
| Spectrum4_000368 | Spectrum5_001553 | Spectrum_000668 |
| Stelazine | Stelazine (*Dihydrochloride*) | Stelazine (Salt/Mix) |
| Synklor (Salt/Mix) | TFP | Terfluzine (Salt/Mix) |
| Trifluoperazin | Trifluoperazin HCl | Trifluoperazina |
| Trifluoperazina [INN-Spanish] | Trifluoperazina [Italian] | Trifluoperazine (INN) |
| Trifluoperazine [INN:BAN] | Trifluoperazine hydrochloride | Trifluoperazinum |
| Trifluoperazinum [INN-Latin] | Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine | Trifluoromethylperazine |
| Trifluoroperazine | Trifluperazine | Triflurin |
| Trifluroperizine | Triftazin (Salt/Mix) | Triftazine (Salt/Mix) |
| Triperazine | Tripfluoperazine Hydrochloride | Triphthasine |
| Triphthazine (Salt/Mix) | UNII-214IZI85K3 | ZEWQUBUPAILYHI-UHFFFAOYSA-N |
| ZINC19418959 | cMAP_000048 | cid_2913535 |
| cid_5566 | trifluoperazine |
| DrugBank Name | Trifluoperazine |
| DrugBank | DB00831 |
| CAS Number | 117-89-5, 440-17-5 |
| PubChem Compound | 5566 |
| KEGG Compound ID | C07168 |
| KEGG Drug | D08636 |
| PubChem.Substance | 46507961 |
| ChEBI | 45951 |
| PharmGKB | PA451771 |
| ChemSpider | 5365 |
| BindingDB | 79181.0 |
| TTD | DAP000034 |
| Wikipedia | Trifluoperazine |
| HET | TFP |
| DPD | 7996|7997 |